Solid Biosciences Approves Equity Plan Amendment at Meeting

Solid Biosciences ( (SLDB) ) just unveiled an announcement.

At the Annual Meeting of Stockholders held on June 12, 2025, Solid Biosciences Inc. announced several key decisions. Stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing the number of shares available by 9,000,000 and adjusting the evergreen provision. Additionally, Alexander Cumbo and Sukumar Nagendran were elected as Class I directors, and the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2025 was ratified. The company also increased its authorized shares from 120,000,000 to 240,000,000 and approved executive compensation.

The most recent analyst rating on (SLDB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Solid Biosciences stock, see the SLDB Stock Forecast page.

Spark’s Take on SLDB Stock

According to Spark, TipRanks’ AI Analyst, SLDB is a Neutral.

Solid Biosciences’ stock score reflects significant financial struggles, with no revenue generation and ongoing losses. The technical analysis presents a mixed view, with indicators suggesting potential overbought conditions despite limited momentum. The valuation is unattractive due to negative earnings and lack of investor returns. Overall, the company’s financial challenges are the most significant factor impacting its stock performance.

To see Spark’s full report on SLDB stock, click here.

More about Solid Biosciences

Average Trading Volume: 1,536,165

Technical Sentiment Signal: Sell

Current Market Cap: $357.3M

For a thorough assessment of SLDB stock, go to TipRanks’ Stock Analysis page.